RNA based antisense drugs: different types, molecular mechanisms and clinical trials

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The Journal of Qazvin University of Medical Sciences

• Publication date

  2014-08-15

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• RNA-based therapies

  2019cited by this paper
• Aptamers in Therapeutics.

  2016cited by this paper
• Down Regulation of ackA-pta Pathway in Escherichia coli BL21 (DE3): A Step Toward Optimized Recombinant Protein Expression System

  2014cited by this paper
• RNA aptamers and their therapeutic and diagnostic applications.

  2013cited by this paper
• Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges

  2013cited by this paper
• Silver nanoscale antisense drug delivery system for photoactivated gene silencing.

  2013cited by this paper
• An open‐label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer

  2012cited by this paper
• RNA-based therapeutics: current progress and future prospects.

  2012cited by this paper
• Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery.

  2012cited by this paper
• Current Progress of RNA Aptamer-Based Therapeutics

  2012cited by this paper
• Current prospects for RNA interference-based therapies

  2011cited by this paper
• An Overview of Sugar‐Modified Oligonucleotides for Antisense Therapeutics

  2011cited by this paper
• Engineering biological systems with synthetic RNA molecules.

  2011cited by this paper
• Special delivery: targeted therapy with small RNAs

  2011cited by this paper
• Antisense drug discovery and development.

  2011cited by this paper
• Strategies in designing multigene expression units to downregulate HIV-1.

  2010cited by this paper
• Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

  2010cited by this paper
• Staying on message: design principles for controlling nonspecific responses to siRNA

  2010cited by this paper
• Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver.

  2010cited by this paper
• RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.

  2010cited by this paper
• INHIBITION OF ACKA AND PTA GENES USING TWO SPECIFIC ANTISENSE RNAS REDUCED ACETATE ACCUMULATION IN BATCH FERMENTATION OF E. COLI BL21 (DE3)

  2010cited by this paper
• Controlled delivery of antisense oligonucleotides: a brief review of current strategies

  2009cited by this paper
• The promises and pitfalls of RNA-interference-based therapeutics

  2009cited by this paper
• Principles of Dicer substrate (D-siRNA) design and function.

  2008cited by this paper
• Prediction of antisense oligonucleotide Efficacy Using Aggregate motifs

  2008cited by this paper
• RNA-based therapies

  2007cited by this paper
• In silico selection of active siRNA.

  2007cited by this paper
• Comparison of approaches for rational siRNA design leading to a new efficient and transparent method

  2007cited by this paper
• Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC

  2007cited by this paper
• RNA interference in embryonic stem cells and the prospects for future therapies

  2006cited by this paper
• An editor's look‐back

  2006cited by this paper
• Design of expression vectors for RNA interference based on miRNAs and RNA splicing

  2006cited by this paper
• Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy

  2005cited by this paper
• Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.

  2005cited by this paper
• Approaches for the sequence-specific knockdown of mRNA

  2003cited by this paper
• Emerging clinical applications of RNA

  2002cited by this paper
• Nucleic-acid therapeutics: basic principles and recent applications

  2002cited by this paper
• The application of ribozymes to HIV infection.

  1999cited by this paper
• In vitro selection of functional nucleic acids.

  1999cited by this paper
• Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

  1998cited by this paper
• Simple RNA enzymes with new and highly specific endoribonuclease activities. 1988.

  1992cited by this paper
• Simple RNA enzymes with new and highly specific endoribonuclease activities

  1988cited by this paper
• The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme.

  1983cited by this paper
• Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena.

  1982influential reference

• Design of antisense oligonucleotides against twist1 gene and evaluation of their anti-invasive effects in prostate cancer cell lines

  2020cites this paper